Tracon Pharmaceuticals, Inc., a biopharmaceutical company based in Foxborough, Massachusetts, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, to deregister securities related to multiple equity incentive plans. The amendments affect a series of registration statements on Form S-8, which were initially filed between January 30, 2015, and March 7, 2024. These registration statements pertain to the company's 2011 Equity Incentive Plan, Amended and Restated 2015 Equity Incentive Plan, and Amended and Restated 2015 Employee Stock Purchase Plan. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. The board of directors approved the dissolution and liquidation of the company, subject to stockholder approval, as disclosed in a Form 8-K filed on July 30, 2024. In line with this, Tracon Pharmaceuticals has decided to terminate the offerings of securities under the affected registration statements and remove any unsold securities from registration.

Tracon Pharmaceuticals, Inc., a biopharmaceutical company based in Foxborough, Massachusetts, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, to deregister securities related to multiple equity incentive plans. The amendments affect a series of registration statements on Form S-8, which were initially filed between January 30, 2015, and March 7, 2024. These registration statements pertain to the company's 2011 Equity Incentive Plan, Amended and Restated 2015 Equity Incentive Plan, and Amended and Restated 2015 Employee Stock Purchase Plan. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. The board of directors approved the dissolution and liquidation of the company, subject to stockholder approval, as disclosed in a Form 8-K filed on July 30, 2024. In line with this, Tracon Pharmaceuticals has decided to terminate the offerings of securities under the affected registration statements and remove any unsold securities from registration.